Targeting a host factor essential for the replication of different viruses but not for the cells offers a higher genetic barrier to the development of resistance, may simplify therapy regimens for coinfections, and facilitates management of emerging viral diseases. DEADbox polypeptide 3 (DDX3) is a human host factor required for the replication of several DNA and RNA viruses, including some of the most challenging human pathogens currently circulating, such as HIV-1, Hepatitis C virus, Dengue virus, and West Nile virus. Herein, we showed for the first time, to our knowledge, that the inhibition of DDX3 by a small molecule could be successfully exploited for the development of a broad spectrum antiviral agent. In addition to the multiple antiviral activities, hit compound 16d retained full activity against drug-resistant HIV-1 strains in the absence of cellular toxicity. Pharmacokinetics and toxicity studies in rats confirmed a good safety profile and bioavailability of 16d. Thus, DDX3 is here validated as a valuable therapeutic target. broad spectrum antivirals | DDX3 | host factors | resistance | coinfections
Targeting a host factor essential for the replication of different viruses but not for the cells offers a higher genetic barrier to the development of resistance, may simplify therapy regimens for coinfections, and facilitates management of emerging viral diseases. DEADbox polypeptide 3 (DDX3) is a human host factor required for the replication of several DNA and RNA viruses, including some of the most challenging human pathogens currently circulating, such as HIV-1, Hepatitis C virus, Dengue virus, and West Nile virus. Herein, we showed for the first time, to our knowledge, that the inhibition of DDX3 by a small molecule could be successfully exploited for the development of a broad spectrum antiviral agent. In addition to the multiple antiviral activities, hit compound 16d retained full activity against drug-resistant HIV-1 strains in the absence of cellular toxicity. Pharmacokinetics and toxicity studies in rats confirmed a good safety profile and bioavailability of 16d. Thus, DDX3 is here validated as a valuable therapeutic target. broad spectrum antivirals | DDX3 | host factors | resistance | coinfections M ost of the current therapeutic approaches to fight viral diseases target unique components or enzymes of a given virus with direct-acting antivirals. Although therapeutically highly successful, direct-acting antivirals are still suffering shortcomings, such as drug resistance, poor adherence in selected patient groups, and associated toxicity (1, 2) . In addition, virtually no broad spectrum antivirals are currently available. An alternative approach currently exploited in antiviral research is the targeting of host proteins. Examples include Maraviroc (approved for the treatment of HIV-1 infection) and Alisporivir [in phase III trials for anti-Hepatitis C virus (HCV) therapy] (3, 4) . Viruses as obligatory parasites dependent on the host cell machinery for replication, protein expression, and assembly of progeny particles (5) (6) (7) . RNA viruses, in particular, have high mutation rates owing to their error-prone polymerases and rapidly generating drug-resistant variants (8) (9) (10) . On this basis, blocking host cell factors required by different viruses for their replication might be a low cost and short time but effective route to develop broad spectrum antivirals able to limit the occurrence of drug resistance (11, 12) .
Recent studies have revealed that the cellular ATPase/RNA helicase X-linked DEAD-box polypeptide 3 (DDX3) is an essential host factor for the replication of viruses belonging to different families: CMV (13) (Herpesviridae), HIV-1 (14) (Retroviridae), HCV (15) (16) (17) (18) , Japanese Encephalitis virus (19) , Dengue virus (DENV) (20) , West Nile virus (WNV; Flaviviridae) (21), Vaccinia virus (22-24) (Poxviridae), and Norovirus (25) (Caliciviridae). The exact mechanisms of interaction of this protein with individual pathogens are still poorly understood (26) . Nonetheless, DDX3 is being regarded as an interesting target for the development of novel antiviral compounds (27, 28) .
For example, targeting DDX3 might offer the possibility of simultaneously treating patients for HIV and HCV coinfections. Several inhibitors of the ATPase activity of DDX3 have been recently identified (29) (30) (31) (32) (33) (34) ; however, an ATP-mimetic compound may have a low degree of selectivity in vivo because of the possibility of interacting with many targets (35) .
Results and Discussion
In a recent work, we designed and validated the first small molecule DDX3 inhibitors, to our knowledge, specifically targeting its RNA binding site ( Fig. 1) (36) . The most promising molecule was compound 2, with both antihelicase activity against DDX3 (IC 50 = 1 μM) and inhibitory effects on HIV-1 replication in peripheral blood mononuclear cells [half-maximal effective concentration (EC 50 ) = 10 μM].
Pursuing this research line, a structure-based optimization process was prosecuted herein on compound 2, resulting in the identification of a new family of more potent DDX3 inhibitors.
Because of the lack of a crystal structure of human DDX3 bound to RNA (closed conformation), we exploited an homology model previously built by us using the closed conformation of Significance Human DEAD-box polypeptide 3 (DDX3) is an ATPase/RNA helicase involved in the replication of many viral pathogens. We reported herein the first inhibitor, to our knowledge, of the helicase binding site of DDX3 endowed with a broad spectrum antiviral activity [HIV-1 WT, HIV drug-resistant strains, Hepatitis C virus (HCV), Dengue virus (DENV), and West Nile virus (WNV)]. The good toxicity profile suggests that the DDX3 activity, although essential for viruses, could be dispensable to the cells, validating DDX3 as a pharmaceutical target. Our results clearly showed that DDX3 inhibitors could be exploited to treat HIV/ HCV coinfections, emerging infectious diseases (such as DENV and WNV), and HIV-1 patients carrying drug-resistant strains. Each of these three medical conditions currently represents a major challenge for clinical treatment. Similar to the RNA strand ( Fig. 2 , yellow stick), compound 2 ( Fig. 2 , green stick) establishes important polar contacts with Arg276, Arg480, and Pro274. Furthermore, it makes hydrophobic interactions with Phe357, His472, Lys451, and Val500. However, our modeling analysis revealed the presence in the binding pocket of two unexplored areas that could be exploited in search of additional interactions (Fig. 2 , cyan and magenta circles). Thus, a small library of compound 2 derivatives has been designed and synthesized, introducing modifications to probe these two regions and expand available structure-activity relationship (SAR) data. Slight modifications included the replacement of the nitro group with the isosteric carboxyl group and the substitution of the methyl-phenyl ring with a cyclohexyl moiety. Furthermore, a naphthyl ring was inserted in place of the tolyl terminus to make additional interactions with Arg503 and Val500. Next, more pronounced substitutions have been made by inserting a substituted triazole ring instead of the nitro group, which allowed the exploration of additional interactions involving residues Arg326 and Gly302. The para position was predicted by docking studies as the most appropriate for such kinds of substitutions, and side chains at four positions were selected, taking into account the interactions into the pocket.
Synthesis of compounds 2-9 ( Fig. S1 ) and 16a-16g ( Fig. S2 ) is reported in Supporting Information.
The anti-DDX3 activity of compounds was assayed, and results are shown in Table 1 . Remarkably, the modifications aimed at optimizing the van der Waals contacts of the ligands with Arg276 and Arg326 (derivatives 16a-16g) resulted in an increase of the helicase inhibitory activity, with the best inhibitors 16d and 16g having IC 50 values of 0.3 and 0.98 μM, respectively.
The inactivity of compound 10 suggests that the presence of an aromatic moiety is fundamental for the helicase inhibitory activity, and is probably due to a crucial cation-π interaction with Arg503. Compounds 9 and 12 unexpectedly precipitated from medium in enzymatic assays and were, thus, found inactive, whereas the ester analog 11 was found moderately active.
The predicted binding mode of 16d within the DDX3 RNA binding pocket is shown in Fig. 3 . Some of the ligand contacts are coincident with the key interactions made by the parent compound 2. Indeed, the urea NH groups were involved in hydrogen bonds with the backbone carbonyl oxygen of Pro274, whereas the triazole ring interacted with the guanidine group of Arg276. Moreover, the tolyl terminus established hydrophobic interactions with residues Arg503 and Pro274, and the phenyl ring made hydrophobic contacts with the aromatic side chain of Phe357. Finally, the butyl substituent at the four position of the triazole ring made profitable interactions with residues Arg326 and Gly302, was unexploited by compound 2, and was probably responsible for the improved antihelicase activity.
According to the proposed mode of binding, 16d behaved as a competitive inhibitor with respect to the RNA substrate, which can be seen by the decrease in its inhibition potency as a function of increasing RNA substrate concentrations (Fig. 4) .
The most active DDX3 inhibitor 16d was then tested against HIV, HCV, WNV, and DENV. Results are summarized in Table  2 . Remarkably, 16d showed a broad spectrum of antiviral activity, being able to inhibit the replication of all of these viruses with EC 50 values ranging from 0.97 to 16.5 μM. No toxicity was found in three different cell culture systems (LucUbiNeo-ET cells and Hepato cellular carcinoma cells) as a demonstration that the inhibition of a cellular cofactor essential for the viruses but not for the cells can represent a successful strategy for the development of novel antiviral agents. For comparison purpose, we also tested hit compound 2 that was previously published (36) against HCVinfected cells, but despite its activity against DDX3, it was found inactive (EC 50 > 86 μM).
The NS3 protein of both HCV and DENV is an RNA helicase that belongs to the same family of DDX3. To exclude the involvement of such viral enzymes in the activities of 16d, we tested this compound against NS3 proteins of HCV and DENV as well as against another cellular member of the DEAD-box family, namely DDX1. We also tested the ability of 16d in the inhibition of the ATPase activity of DDX3. As shown in Table 3 , 16d was found to be completely inactive against the ATPase of DDX3, DDX1 helicase, and DENV NS3 helicase. It showed moderate activity against the HCV NS3 helicase, which was, however, 56and 17-fold lower than the activity against DDX3 helicase and HCV proliferation, respectively.
The antiviral activity of compound 16d was also evaluated against HIV-1 strains carrying clinically relevant mutations conferring highlevel resistance to most classes of antivirals approved to treat HIV infection ( Table 4 and Table S1 ). Compound 16d retained full activity against all of the resistant viruses tested, confirming its novel mechanism of action and the potential to overcome HIV resistance.
A few in vitro experiments were then conducted to quickly establish the absorption/stability of compound 16d: aqueous solubility (pH 7.4 buffer), parallel artificial membrane permeability assay, and human liver microsome stability determination ( Table 5 ). Despite the fact that the aqueous solubility is just outside of the range of recommended values for a drug (−6 < LogS < −1), the excellent metabolic stability and the good passive membrane permeability make 16d a good lead candidate for additional development.
To better evaluate toxicity and biodistribution of compound 16d, we finally performed several preliminary in vivo studies; 16d was administered to Wistar rats by tail vein in a single systemic dose (0.05 mL per dose) at high-dose levels of 20 mg/kg. There were no treatment-related adverse effects on clinical chemistry analysis of serum for the measurement of biochemical parameters (including liver enzymes, such as alanine aminotransferase, aspartate aminotransferase, and glutamate dehydrogenase), urea, creatinine, triglycerides, LDLs, and HDLs. Urine analysis parameters for treated rats did not show any significant difference from the respective control groups. Histopathological analysis of the liver was free from any pathological abnormality, and H&E-stained sections appeared normal, with regular cellular architecture. The hepatic cells had intact cytoplasm, sinusoidal spaces, prominent nucleus, and nucleolus ( Fig. 5 ). Renal tissue of all animal groups showed preserved renal parenchyma with normal appearance of glomerular tuft and urinary space ( Fig. 5 ). Also, histological analyses of brain tissue samples showed no obvious uncharacteristic changes in all animal groups. In conclusion, 16d was found to possess excellent biocompatibility, and Wistar rats showed a good tolerance to the dose of 20 mg/kg.
The pharmacokinetic analysis of compound 16d was finally conducted. The main pharmacokinetic parameters from singlecompartment model analysis are summarized in Table 6 . The half-life elimination and the plasmatic clearance values denoted that 16d was rapidly eliminated after i.v. administration.
The mean plasma concentration-time curves after i.v. administration are illustrated in Fig. 6A . Tissue distribution of 16d in rat after i.v. administration is presented in Fig. 6B . Higher concentration of 16d was found in adipose tissue followed by kidney, testicle, liver, and brain in that order, which can be attributed to the blood flow in this organs.
In conclusion, we report herein the discovery of a novel series of human helicase DDX3 inhibitors. Among them, compound 16d represents the first compound, to our knowledge, achieving broad spectrum antiviral activity (HIV, HCV, DENV, and WNV) in infected cells, targeting a host factor. Compound 16d was active against HIV-1 drug-resistant strains, suggesting that DDX3 targeting agents may be able to treat HIV/HCV coinfections, patients harboring drug-resistant viruses, and emerging viral diseases, for which no specific drugs are available. Moreover, the good toxicity profile suggests that the DDX3 activity, although essential for viral replication, may be dispensable to the cell as shown by preclinical studies. This result represents a step forward in the fight against infectious diseases and opens a new scenario in the drug development process.
Materials and Methods
Detailed procedures for the synthesis and characterization of compounds are provided in Supporting Information.
Absorption, distribution, metabolism, and excretion (ADME) experiments, assay protocols, and pharmacokinetic and toxicity studies can be found in Supporting Information.
The rat experiments were performed under a protocol approved by the Institutional Animal Use and Care Committee at the Università Cattolica del Sacro Cuore (permit no. EE21; March 18, 2014) 
